Overview

Bevacizumab Versus Ranibizumab in Age Related Macular Degeneration

Status:
Unknown status
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
To report the short term anatomic and visual acuity response after intravitreal injection of bevacizumab and ranibizumab in patients with choroidal neovascularization secondary to age-related macular degeneration.
Phase:
Phase 3
Details
Lead Sponsor:
Instituto de Olhos de Goiania
Treatments:
Bevacizumab
Ranibizumab